PHASE III STUDY OF NUTROPIN THERAPY IN PUBERTAL CHILDREN WITH GH DEFICIENCY

生长激素缺乏症青春期儿童 Nutropin 治疗的 III 期研究

• 批准号: 6307461
• 负责人: ALAN D ROGOL
• 金额: $ 2.81万
• 依托单位: UNIVERSITY OF VIRGINIA
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2001-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6307461
• 关键词: adolescence (12-20); clinical research; drug administration rate /duration; hormone therapy; human puberty; human subject; human therapy evaluation; injection /infusion; pituitary dwarfism; somatotropin

Growth hormone release increases 2- to 3-fold at puberty in GH sufficient children. To determine if these increased amounts of GH are required for optimal growth, pubertal GH deficient boys and girls will receive GH at one of two doses - the standard 0.3 mg/kg/week or 0.7 mg/kg/week given daily subcutaneously.

生长激素充足的儿童在青春期生长激素释放增加2- 3倍。为了确定最佳生长是否需要这些增加的生长激素，青春期生长激素缺乏的男孩和女孩将接受两种剂量中的一种——标准的0.3毫克/公斤/周或0.7毫克/公斤/周皮下注射。